NR 567 Advanced Pharmacology AGACNP Final Exam
2026/2027 | 60 Verified Questions & Answers | Chamberlain
University NP Prep | 6 Core Domains | Instant Download .
INTRODUCTION
NR 567: Advanced Pharmacology for the AGACNP (Adult-Gerontology Acute Care Nurse Practitioner) is a
rigorous course in the Chamberlain University MSN program. This comprehensive final examination
covers 6 core domains of advanced pharmacotherapeutics essential for acute care practice.
The AGACNP role requires expert knowledge of pharmacokinetics, pharmacodynamics, and the clinical
application of pharmacologic agents in high-acuity settings. This examination evaluates the candidate's
ability to:
• Apply advanced pharmacokinetic and pharmacodynamic principles to complex patient
scenarios
• Select and manage evidence-based pharmacologic therapies for acute and critical care
conditions
• Recognize and manage adverse drug events and drug interactions
• Individualize therapy based on patient-specific factors (renal/hepatic function, age, genetics,
comorbidities)
• Optimize medication safety and quality in acute care settings
Domain Approximate Weight
Pharmacokinetics & Pharmacodynamics 20%
Cardiovascular & Hematologic Pharmacology 20%
Respiratory & Infectious Disease Pharmacology 15%
Endocrine & Metabolic Pharmacology 15%
Neurologic, Psychiatric & Pain Management 15%
Pharmacogenomics, Drug Interactions & Safety 15%
,SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS
Question 1:
A patient with acute decompensated heart failure is started on furosemide. Which pharmacokinetic
parameter is most important to consider when determining the frequency of dosing?
A) Volume of distribution (Vd)
B) Half-life (t½)
C) Bioavailability (F)
D) Protein binding
Correct Answer: B) Half-life (t½)
Rationale: The half-life (t½) determines the time required for the drug concentration to decrease by
50% and is used to determine dosing frequency and the time to reach steady state. Furosemide has a
relatively short half-life (0.5-2 hours), requiring multiple daily dosing. Vd affects the loading dose,
bioavailability affects the oral dose, and protein binding affects drug distribution and interactions.
Question 2:
A 72-year-old patient with chronic kidney disease (eGFR 25 mL/min) is prescribed a medication that is
primarily renally excreted. Which pharmacokinetic change should the AGACNP anticipate?
A) Increased clearance
B) Decreased clearance and prolonged half-life
C) Increased volume of distribution
D) Decreased bioavailability
Correct Answer: B) Decreased clearance and prolonged half-life
Rationale: In chronic kidney disease, decreased renal clearance leads to prolonged half-life and
increased drug accumulation, increasing the risk of toxicity. Dose adjustments (either decreased dose or
increased dosing interval) are required for renally excreted medications.
Question 3:
Which of the following best describes the first-pass effect?
A) Metabolism of a drug in the liver before it reaches systemic circulation
B) Excretion of a drug in the bile
C) Distribution of a drug to the brain
D) Binding of a drug to plasma proteins
Correct Answer: A) Metabolism of a drug in the liver before it reaches systemic circulation
, Rationale: The first-pass effect refers to the metabolism of a drug in the liver (and intestinal wall) before
it reaches systemic circulation. Drugs with extensive first-pass metabolism have low oral bioavailability
and may require higher oral doses or alternative routes (IV, sublingual, transdermal).
Question 4:
A drug with a narrow therapeutic index requires:
A) Routine monitoring of serum drug levels
B) No monitoring
C) High doses
D) Rapid titration
Correct Answer: A) Routine monitoring of serum drug levels
Rationale: Drugs with a narrow therapeutic index (NTI) have a small range between therapeutic and
toxic doses. Examples include digoxin, lithium, warfarin, phenytoin, and vancomycin. Therapeutic drug
monitoring (TDM) is essential to maintain levels within the therapeutic range and prevent toxicity.
Question 5:
A patient is prescribed a medication that is a CYP3A4 inhibitor. What is the anticipated effect on other
medications metabolized by CYP3A4?
A) Decreased levels of other medications
B) Increased levels of other medications
C) No effect on other medications
D) Increased renal excretion
Correct Answer: B) Increased levels of other medications
Rationale: CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, grapefruit juice) decrease the
metabolism of CYP3A4 substrate drugs, leading to increased drug levels and potential toxicity. Careful
monitoring and dose adjustments are required.
Question 6:
A patient with cirrhosis is prescribed a medication that undergoes extensive hepatic metabolism. What
pharmacokinetic change should the AGACNP anticipate?
A) Increased metabolism
B) Decreased metabolism and increased risk of toxicity
C) Increased renal excretion
D) Decreased protein binding
Correct Answer: B) Decreased metabolism and increased risk of toxicity
2026/2027 | 60 Verified Questions & Answers | Chamberlain
University NP Prep | 6 Core Domains | Instant Download .
INTRODUCTION
NR 567: Advanced Pharmacology for the AGACNP (Adult-Gerontology Acute Care Nurse Practitioner) is a
rigorous course in the Chamberlain University MSN program. This comprehensive final examination
covers 6 core domains of advanced pharmacotherapeutics essential for acute care practice.
The AGACNP role requires expert knowledge of pharmacokinetics, pharmacodynamics, and the clinical
application of pharmacologic agents in high-acuity settings. This examination evaluates the candidate's
ability to:
• Apply advanced pharmacokinetic and pharmacodynamic principles to complex patient
scenarios
• Select and manage evidence-based pharmacologic therapies for acute and critical care
conditions
• Recognize and manage adverse drug events and drug interactions
• Individualize therapy based on patient-specific factors (renal/hepatic function, age, genetics,
comorbidities)
• Optimize medication safety and quality in acute care settings
Domain Approximate Weight
Pharmacokinetics & Pharmacodynamics 20%
Cardiovascular & Hematologic Pharmacology 20%
Respiratory & Infectious Disease Pharmacology 15%
Endocrine & Metabolic Pharmacology 15%
Neurologic, Psychiatric & Pain Management 15%
Pharmacogenomics, Drug Interactions & Safety 15%
,SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS
Question 1:
A patient with acute decompensated heart failure is started on furosemide. Which pharmacokinetic
parameter is most important to consider when determining the frequency of dosing?
A) Volume of distribution (Vd)
B) Half-life (t½)
C) Bioavailability (F)
D) Protein binding
Correct Answer: B) Half-life (t½)
Rationale: The half-life (t½) determines the time required for the drug concentration to decrease by
50% and is used to determine dosing frequency and the time to reach steady state. Furosemide has a
relatively short half-life (0.5-2 hours), requiring multiple daily dosing. Vd affects the loading dose,
bioavailability affects the oral dose, and protein binding affects drug distribution and interactions.
Question 2:
A 72-year-old patient with chronic kidney disease (eGFR 25 mL/min) is prescribed a medication that is
primarily renally excreted. Which pharmacokinetic change should the AGACNP anticipate?
A) Increased clearance
B) Decreased clearance and prolonged half-life
C) Increased volume of distribution
D) Decreased bioavailability
Correct Answer: B) Decreased clearance and prolonged half-life
Rationale: In chronic kidney disease, decreased renal clearance leads to prolonged half-life and
increased drug accumulation, increasing the risk of toxicity. Dose adjustments (either decreased dose or
increased dosing interval) are required for renally excreted medications.
Question 3:
Which of the following best describes the first-pass effect?
A) Metabolism of a drug in the liver before it reaches systemic circulation
B) Excretion of a drug in the bile
C) Distribution of a drug to the brain
D) Binding of a drug to plasma proteins
Correct Answer: A) Metabolism of a drug in the liver before it reaches systemic circulation
, Rationale: The first-pass effect refers to the metabolism of a drug in the liver (and intestinal wall) before
it reaches systemic circulation. Drugs with extensive first-pass metabolism have low oral bioavailability
and may require higher oral doses or alternative routes (IV, sublingual, transdermal).
Question 4:
A drug with a narrow therapeutic index requires:
A) Routine monitoring of serum drug levels
B) No monitoring
C) High doses
D) Rapid titration
Correct Answer: A) Routine monitoring of serum drug levels
Rationale: Drugs with a narrow therapeutic index (NTI) have a small range between therapeutic and
toxic doses. Examples include digoxin, lithium, warfarin, phenytoin, and vancomycin. Therapeutic drug
monitoring (TDM) is essential to maintain levels within the therapeutic range and prevent toxicity.
Question 5:
A patient is prescribed a medication that is a CYP3A4 inhibitor. What is the anticipated effect on other
medications metabolized by CYP3A4?
A) Decreased levels of other medications
B) Increased levels of other medications
C) No effect on other medications
D) Increased renal excretion
Correct Answer: B) Increased levels of other medications
Rationale: CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, grapefruit juice) decrease the
metabolism of CYP3A4 substrate drugs, leading to increased drug levels and potential toxicity. Careful
monitoring and dose adjustments are required.
Question 6:
A patient with cirrhosis is prescribed a medication that undergoes extensive hepatic metabolism. What
pharmacokinetic change should the AGACNP anticipate?
A) Increased metabolism
B) Decreased metabolism and increased risk of toxicity
C) Increased renal excretion
D) Decreased protein binding
Correct Answer: B) Decreased metabolism and increased risk of toxicity
